Epigral Ltd
Epigral Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #27 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
From Epigral Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand.
- Q4 FY '26 volumes likely to improve with uptick in demand from mid-November and better market conditions.
- CPVC demand projected to grow 10-12% annually, anticipated to reach around 320,000 tonnes by FY '27 end, with long-term growth towards 500,000 tonnes by FY '30.
- Chlorotoluene segment expected to contribute sizable revenue from FY '27 onwards, with major orders and contracts starting Q1 FY '27.
- Epigral is commissioning expansions in CPVC and epichlorohydrin capacity; initial lower utilization expected post-commissioning but achieving optimal utilization within 1-2 years.
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule.
- Projects to double capacity at CPVC and epichlorohydrin, and wind solar hybrid power plants on track for commissioning within announced timeline and budget.
- Chlorotoluene value chain plant commissioned in March 2025, expected to contribute significantly to profit from FY27 onwards.
- New projects’ capex plans are being finalized, with details expected to be announced in the coming months.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Chlorotoluene segment orders are currently on a quarterly basis as customers are testing and building confidence.
- Actual deliveries are happening on a full truckload basis, not just samples.
- Major volume orders and long-term contracts are expected to begin from FY '27 onwards.
- The company anticipates a sizable revenue contribution from the chlorotoluene plant starting Q1 FY '27.
- As approvals and customer contracts finalize, order visibility will improve by March.
2 more points from Epigral Ltd's call on order book
Create a free account to keep reading this call
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio Solutions Ltd (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q3 FY26 results?
FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.